Compare Abbott Laboratories (ABT) vs Chewy Inc (CHWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Chewy Inc — how do they compare? Abbott Laboratories trades at $95.41 (market cap $166.94B), while Chewy Inc trades at $20.72 (market cap $8.49B). The key difference: Abbott Laboratories is far larger — about 19.7× Chewy Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| ABT | CHWY | |
|---|---|---|
Market Cap | $166.94B | $8.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $42.33 |
52-Week Low | $82.57 | $17.51 |
Enterprise Value | $193.69B | $8.45B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Chewy (CHWY) trades at $20.73, down 0.58% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported $11.86B in revenue for 2025 with a net income margin of 1.99%, showing improved profitability from prior years. Recent news highlights market share gains through its Autoship program and expansion into pet healthcare services, though the stock faces pressure from lowered 2026 growth expectations.
The outlook remains positive with an 81.58% buy rating from analysts and a $34.92 consensus price target, suggesting significant upside. Key risks include competitive pressures in the pet care sector and execution challenges in integrating new veterinary services. Investors should weigh strong customer loyalty and recurring revenue streams against near-term volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
